You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. *Average returns of all recommendations since inception. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. 7 Travel Stocks to Buy Banking On Pent-Up Demand. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. Keith Speights for David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! From a near-term standpoint, there are two key risks. Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. Maybe OCGN stock will be one of them again. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. If were playing that game then Im buying LEAP call options on Apple and Amazon in March. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. First, the balance sheet is in at least decent shape. The FDA's decision not to issue EUA really wasn't all that surprising, though. Keith Speights has no position in any of the stocks mentioned. Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. If youre not convinced by now, maybe you will consider OCGN stock a poor investment when looking at the fundamentals. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. As of this writing, Vince Martin has no positions in any securities mentioned. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. The Motley Fool has no position in any of the stocks mentioned. For now, though, what happens in India stays in India. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. See disclosure here. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. Here are three prudent steps to take. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. To make the world smarter, happier, and richer. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. Custom BMW. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. So, what goes wrong? In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Unfortunately for longs, OCGN is much closer to the worst of conditions. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. Can you feel the ground moving beneath your feet? I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. Ocugen Inc. is a clinical stage biopharmaceutical company. You never know when they will suddenly go on a squeeze. If they have solid financials, but their trials continually fail, they will likely not succeed. That's right -- they think these 10 stocks are even better buys. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Investors were hopeful that the small drugmaker would be able to win U.S. Do Not Sell My Personal Information (CA Residents Only). The content is intended to be used for informational purposes only. The Motley Fool has a disclosure policy. Keith Speights has no position in any of the stocks mentioned. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. The Motley Fool has no position in any of the stocks mentioned. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. What should investors do now? However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. The statistics support having long-term exposure to this asset class. Thats the thing with these low-priced penny stocks. The company stated that it will pursue a path to file for full FDA approval of Covaxin. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. 1125 N. Charles St, Baltimore, MD 21201. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Written by It has real products. Ill be sticking to the stocks that are actually working. The short answer is: everything. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. In this case, shares rallied about four-fold in just a few days. Making the world smarter, happier, and richer. The Motley Fool recommends Moderna Inc. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Emergency Use . Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Do not expect a recovery in Ocugen stock. The Ocugen deal is a way to salvage some limited value. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. Pricing likely would be favorable, given the lack of alternative treatments. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. And its at least possible that OCGN could wind up being a winner. Hold) without suggesting a price target. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ocugen estimates the drug could have as many as 63,000 potential patients. Please check your download folder. Invest better with The Motley Fool. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. The Motley Fool->. If you missed that action, you missed all the gains. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. CanSinoBio will receive some of the profits, but Ocugen still would skyrocket with FDA approval and ensuing revenue and there are more products in the pipeline. And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. Our 3 Top Picks. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. Click here to see what Matt has up his sleeve now. Nasdaq Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. It means that raising capital will be more difficult going forward. It has no treatments to offer the market. OCGN Ocugen Inc 155,223 $0.9721 $0.0263 (2.63%) In November, Bharat Biotech began Phase 3 testing of Covaxin in India. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. Copy and paste multiple symbols separated by spaces. The latest closing stock price for Ocugen as of March 03, 2023 is. If they invent a miracle treatment for a condition, the money will find its way to the stock. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Written by Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Copyright 2023 InvestorPlace Media, LLC. This requires no immediate effort on your part. Copyright 2023 InvestorPlace Media, LLC. But the allure of the space is that when a company wins, its shareholders win big. All rights reserved. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. This decision. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). All rights reserved. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. 1125 N. Charles St, Baltimore, MD 21201. These options will be cheaper than owning the stock itself. But realizing value in practice usually is a difficult endeavor. Do Not Sell My Personal Information (CA Residents Only). CFO Sanjay Subramanian said that there was "the potential for near-term revenue," depending on the EUA. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). quotes delayed at least 15 minutes, all others at least 20 minutes. The stock ultimately hit its 2020 low on June 1 at a price of just 17 cents. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. However, even from this limited vantage point, OCGN appears destined to fail. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Bharat Biotech has a history of successful vaccine commercialization in South Asia. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. That product drives the current bull case for Ocugen stock. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Create your Watchlist to save your favorite quotes on Nasdaq.com. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. quotes delayed at least 15 minutes, all others at least 20 minutes. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. market." Keith Speights for The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. But it does mean something. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. Keith Speights owns shares of Pfizer. Start trading Options with Saxo today. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. 1125 N. Charles St, Baltimore, MD 21201. Even at around 40 cents per share, I would consider Ocugen stock overvalued. OCGN does not even appear to have an apparent reason to exist. Investors should worry about companies with no revenue even under the best of circumstances. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. The company initiated its Phase 3 trial of OCU300 back in July 2018. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. Nasdaq Companies will inevitably be optimistic about their prospects for success (at least publicly). The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Like other life sciences companies involved in Covid-19 vaccine. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. The stock had gained some traction after they announced the Ocugen merger in April. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. But there is no question some big-name stocks performed better than others along the way. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. Its worth emphasizing: Ocugen stock is a play with enormous risk. It is very important to do your own analysis before making any investment. While anything is possible, I would not anticipate a miracle here. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. For investors new to the story, there are some positives when it comes to OCGN stock. Instead, this appears destined to join the long list of failed biotech startups. (See OCGN stock analysis on TipRanks). That said, for investors who understand the potential downside, there is an intriguing story here. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. At the time, Ocugen was left for dead. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. Buy These 2 Stocks in 2023 and Hold for the Next Decade, 2 Stocks That Are About to Make Their Shareholders Richer, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, the company's fourth-quarter conference call last month, Copyright, Trademark and Patent Information. The Ocugen deal is a way to salvage some limited value. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." To be sure, current cash isnt enough. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. 2023 InvestorPlace Media, LLC. Sign up below to get this incredible offer! Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. That doesnt mean success is guaranteed. But just because a company does not have crippling debt doesnt mean its a buy. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor.

Party City Distribution Center Locations, Distinct Ideas Of Karol Wojtyla About Intersubjectivity, C3h3o2 Lewis Structure, Articles O